Back to Search
Start Over
Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B
- Source :
- Experimental and Therapeutic Medicine
- Publication Year :
- 2020
- Publisher :
- D.A. Spandidos, 2020.
-
Abstract
- Chronic hepatitis B (CHB) virus continues to be a leading cause of morbidity and mortality worldwide. The diagnosis of liver fibrosis has a key role in selecting patients with CHB for antiviral treatment. However, serum biomarkers demonstrate limited diagnostic utility. The present study aimed to compare the performances of fibrosis biomarkers for diagnosing significant liver fibrosis that indicates the need for antiviral therapy in patients with CHB and to identify the most appropriate biomarker for these patients. The current study included 96 antiviral-naive patients with CHB who underwent liver biopsy. METAVIR scoring system was used to assess liver fibrosis and necroinflammation. The diagnostic performances were evaluated of the platelet (PLT) count; the levels of hyaluronan, serum 7S domain of type 4 collagen, procollagen type III N-terminal peptide, tissue inhibitor of metalloproteinases 1, Mac-2 binding protein glycosylation isomer (M2BPGi) and N-terminal type III collagen propeptide (Pro-C3); the fibrosis index based on four factors; the aspartate aminotransferase-to-platelet ratio index; and enhanced liver fibrosis score for identifying significant liver fibrosis [≥fibrosis stage 2 (F2)]. All fibrosis biomarkers, except the Pro-C3 level, correlated with the fibrosis stage. M2BPGi was better than other biomarkers for diagnosing ≥F2, with the highest area under the curve of 0.902. M2BPGi demonstrated a higher diagnostic accuracy for significant fibrosis than mild/severe fibrosis or cirrhosis. However, no significant correlation was observed between the M2BPGi level and fibrosis stage in patients with CHB having significant liver necroinflammation defined as ≥ necroinflammatory activity 2. The M2BPGi level and PLT count were exclusively correlated with the fibrosis stage in 73 patients without significant liver necroinflammation. M2BPGi demonstrated the highest diagnostic performance for significant fibrosis in patients having significant liver fibrosis with no significant liver necroinflammation. In conclusion, the M2BPGi level can accurately diagnose significant liver fibrosis that indicates the need for antiviral therapy in patients with CHB.
- Subjects :
- 0301 basic medicine
Cancer Research
medicine.medical_specialty
Cirrhosis
liver necroinflammation
Mac-2 binding protein glycosylation isomer
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Immunology and Microbiology (miscellaneous)
Fibrosis
Internal medicine
medicine
chronic hepatitis B
N-terminal type III collagen propeptide
Stage (cooking)
liver fibrosis
medicine.diagnostic_test
business.industry
Area under the curve
Cancer
General Medicine
Articles
medicine.disease
Molecular medicine
030104 developmental biology
030220 oncology & carcinogenesis
Liver biopsy
Biomarker (medicine)
business
Subjects
Details
- Language :
- English
- ISSN :
- 17921015 and 17920981
- Volume :
- 20
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Experimental and Therapeutic Medicine
- Accession number :
- edsair.doi.dedup.....7fac9f7aee088ea739da26b824ede81f